Appendix Iv Statutory and General Information

Total Page:16

File Type:pdf, Size:1020Kb

Appendix Iv Statutory and General Information This document is in draft form, incomplete and subject to change and that the information must be read in conjunction with the section headed “Warning” on the cover of this document. APPENDIX IV STATUTORY AND GENERAL INFORMATION A. FURTHER INFORMATION ABOUT OUR GROUP 1. Incorporation of Our Company We were incorporated in the Cayman Islands under the Cayman Companies Law as an exempted company with limited liability on November 15, 2013. We have established a principal place of business in Hong Kong at 8th Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong and have been registered with the Registrar of Companies in Hong Kong as a non-Hong Kong company under Part XI of the old Companies Ordinance (Chapter 32 of the Laws of Hong Kong which was in effect until March 3, 2014) on January 6, 2014. Ms. Lai Siu Kuen has been appointed as the authorized representative of our Company for the acceptance of service of process and notices in Hong Kong. As we were incorporated in the Cayman Islands, our corporate structure and Memorandum of Association and Articles of Association are subject to the relevant laws and regulations of the Cayman Islands. A summary of the relevant laws and regulations of the Cayman Islands and of the Memorandum of Association and Articles of Association is set out in the section headed ‘‘Summary of the Constitution of Our Company and Cayman Companies Law’’ in Appendix III to this [REDACTED]. 2. Changes in the Share Capital of Our Company As of the date of incorporation of our Company, our Company had an authorized share capital of HK$380,000, divided into 38,000,000 shares of HK$0.01 each. The following changes in the share capital of our Company have taken place since the date of incorporation of our Company up to the date of this [REDACTED]: . On November 15, 2013, we allotted and issued one Share to Walkers Nominees Limited at par value, which was transferred to Fresh Water Group on November 19, 2013. On March 18, 2014, we allotted and issue one Share to Fresh Water Group at a subscription price of RMB600,000. The following changes in the share capital of our Company will take place after the date of this [REDACTED]: . Upon the [REDACTED] becoming unconditional, the authorized share capital of our Company will be increased from HK$380,000 to HK$40,000,000 by the creation of an additional 3,962,000,000 Shares. Immediately following the [REDACTED] becoming unconditional, 1,265,999,998 Shares will be allotted and issued, credited as fully paid, to Fresh Water Group pursuant to the Capitalization Issue, and Fresh Water Group will transfer 341,820,000 Shares to Baida Holdings Limited, 54,058,200 Shares to Lion Rise Holdings Limited, 50,640,000 Shares to Glorious Shine Holdings Limited, – IV-1 – This document is in draft form, incomplete and subject to change and that the information must be read in conjunction with the section headed “Warning” on the cover of this document. APPENDIX IV STATUTORY AND GENERAL INFORMATION 69,883,200 Shares to Baoye International Limited, 41,778,000 Shares to Giant Century International Limited, 334,857,000 Shares to SAIF Partners IV L.P., 233,956,800 Shares to Ares FW Holdings, L.P., 139,006,800 Shares to Watercube Holdings, L.L.C. in consideration of the repurchase by Fresh Water Group of its issued shares from Mr. Xiao, Mr. Wang, SAIF Partners IV L.P., Ares FW Holdings, L.P. and Watercube Holdings, L.L.C.Note Note: Baida Holdings Limited, Lion Rise Holdings Limited and Glorious Shine Holdings Limited are wholly-owned by Baida Capital Limited, Lion Rise Capital Limited and Glorious Shine Capital Limited under the Xiao Family I Trust, the Xiao Family II Trust and the Xiao Family III Trust, respectively. Each of the Xiao Family I Trust, the Xiao Family II Trust and the Xiao Family III TrustisadiscretionarytrustestablishedbyMr. Xiao (as the settlor) and the discretionary beneficiaries of which include Mr. Xiao and certain of his family members. Fresh Water Group transferred an aggregate of 446,518,200 Shares to Baida Holdings Limited, Lion Rise Holdings Limited and Glorious Shine Holdings Limited at the direction of Mr. Xiao. Baoye International Limited and Giant Century International Limited are wholly-owned by Baoye Capital Limited and Giant Century Capital Limited under the Wang Family I Trust and the Wang Family II Trust, respectively. Each of the Wang Family I Trust and the Wang Family IITrustisadiscretionarytrustestablishedby Mr. Wang (as the settlor) and the discretionary beneficiaries of which include Mr. Wang and his spouse. Fresh Water Group transferred an aggregate of 111,661,200 Shares to Baoye International Limited and Giant Century International Limited at the direction of Mr. Wang. Assuming that the [REDACTED] becomes unconditional, the authorized share capital of our Company will be increased from HK$380,000 to HK$40,000,000 divided into 4,000,000,000 Shares on the Listing Date, and assuming further that the Capitalization Issue is completed and the [REDACTED] are issued but without taking into account any Shares which may be issued upon the exercise of the Over-allotment Option and options which were granted under the Pre-[REDACTED] Share Option Scheme or may be granted under the Share Option Scheme, the issued share capital of our Company will be HK$[REDACTED], divided into [REDACTED] Shares, all fully paid or credited as fully paid, with [REDACTED] Shares remain unissued. Save as disclosed above and in this [REDACTED], there has been no alteration in the share capital of our Company since our incorporation. – IV-2 – This document is in draft form, incomplete and subject to change and that the information must be read in conjunction with the section headed “Warning” on the cover of this document. APPENDIX IV STATUTORY AND GENERAL INFORMATION 3. Resolutions in Writing of the Sole Shareholder of Our Company Pursuant to the written resolutions passed by the sole Shareholder on May 26, 2014, it was resolved, among others, (a) conditional on (1) the Listing Committee granting approval for the listing of, and permission to deal in, the Shares in issue and to be issued as mentioned in this [REDACTED], (2) the [REDACTED] being fixed on the Price Determination Date and (3) the obligations of the Underwriters under the Underwriting Agreements becoming unconditional and not being terminated in accordance with the terms therein (unless and to the extent such conditions are validly waived on or before such dates as may be specified in the Underwriting Agreements) or otherwise: (i) our Company approved and adopted the Memorandum and Articles of Association with effect from the date of Listing; (ii) the authorized share capital of our Company was increased from HK$380,000 to HK$40,000,000 by the creation of an additional 3,962,000,000 Shares with a nominal value of HK$0.01 each; (iii) the [REDACTED] and the Over-allotment Option were approved and the Directors were authorized to allot and issue the new Shares pursuant to the [REDACTED] and the Over-allotment Option; (iv) the proposed Listing was approved and the Directors were authorized to implement the Listing; (v) subject to the share premium account of our Company having sufficient balance, or otherwise being credited as a result of the issue of [REDACTED] pursuant to the [REDACTED], our Directors were authorized to allot and issue a total of 1,265,999,998 Shares credited as fully paid at par to the holder(s) of Shares on the register of members of our Company at the close of business on the date of passing this resolution (or as it/they may direct) in proportion to its/their respective shareholdings in the Company (as nearly as possible without fractions) by way of capitalization of the sum of HK$12,659,999.98 standing to the credit of the share premium account of our Company, and the Shares to be allotted and issued pursuant to this resolution shall rank pari passu in all respects with the then existing issued Shares; (vi) a general unconditional mandate was granted to the Directors to allot, issue and deal with Shares or securities convertible into Shares or options, warrants or similar rights to subscribe for Shares or such convertible securities and to make or grant offers, agreements or options which would or might require the exercise of such powers, provided that the aggregate nominal value of Shares allotted or agreed to be allotted by the Directors other than pursuant to (i) a rights issue, (ii) any scrip dividend scheme or similar arrangement providing for the allotment of Shares in lieu of the – IV-3 – This document is in draft form, incomplete and subject to change and that the information must be read in conjunction with the section headed “Warning” on the cover of this document. APPENDIX IV STATUTORY AND GENERAL INFORMATION whole or part of a dividend on Shares in accordance with the Articles of Association, (iii) the exercise of options granted pursuant to the Pre- [REDACTED] Share Option Scheme and/or options to be granted pursuant to the Share Option Scheme or (iv) theexerciseofanysubscriptionor conversion rights attaching to any warrants or securities which are convertible into Shares or in issue prior to the date of passing the relevant resolution or (v) a specific authority granted by the Shareholders in general meeting, shall not exceed the aggregate of (1) 20% of the total nominal value of the share capital of our Company in issue immediately following the completion of the Capitalization Issue and the [REDACTED] (but excluding any Shares which may be issued pursuant to the
Recommended publications
  • SEC61G Is Upregulated and Required for Tumor Progression in Human Kidney Cancer
    MOLECULAR MEDICINE REPORTS 23: 427, 2021 SEC61G is upregulated and required for tumor progression in human kidney cancer HUI MENG1, XUEWEN JIANG1, JIAN WANG2, ZUNMENG SANG1, LONGFEI GUO1, GANG YIN1 and YU WANG3 1Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012; 2Department of Urology, People's Hospital of Laoling, Laoling, Shandong 253600; 3Reproductive Medicine Center, Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China Received December 16, 2019; Accepted January 29, 2021 DOI: 10.3892/mmr.2021.12066 Abstract. Kidney cancer is a malignant tumor of the urinary promote kidney tumor progression. Therefore, the present system. Although the 5‑year survival rate of patients with study provided a novel candidate gene for predicting the kidney cancer has increased by ~30% in recent years due to prognosis of patients with kidney cancer. the early detection of low‑grade tumors using more accurate diagnostic methods, the global incidence of kidney cancer Introduction continues to increase every year. Therefore, identification of novel and efficient candidate genes for predicting the prog‑ Kidney cancer is a malignant tumor of the urinary system, nosis of patients with kidney cancer is important. The present accounting for 2.2% of all adult malignancies worldwide (1). study aimed to investigate the role of SEC61 translocon The most common type of kidney cancer is renal cell carci‑ subunit‑γ (SEC61G) in kidney cancer. The Cancer Genome noma (RCC), which accounts for 85‑90% of all cases (2). Atlas database was screened to obtain the expression profile According to the classification of International Society of of SEC61G and identify its association with kidney cancer Urological Pathology, RCC is primarily divided into three prognosis.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Shandong Dezhou Investment Delegation to ASEAN
    Shandong Dezhou Investment Delegation to ASEAN CONTENTS Social and Economic Survey of Dezhou………………………………………………………………………….2 Competitive Industry of Dezhou....…………………………………………………………………………………4 CCPIT Dezhou Branch & CCIOC Dezhou Chamber…………………………………………………………..9 Shandong Dexing Group Construction Engineering Co., Ltd…………………………………………..11 Shandong Huahai Group Co., Ltd…………………………………………………………………………………13 Shandong Xin jiekou Culturaland Creative Industrial Zone …………………………………………..15 Shandong K.D.L. Textile Co., Ltd…..………………………………………………………………………………17 Dezhou Liyuan International Co.,Ltd……………………………………………………………………………19 Dezhou Huaqiang Trade Co. Ltd.………………………………………………………………………………….21 Shandong Dexing Group Gear Logistics Co., Ltd……………………………………………………………23 Hebei Dongfang Iron Tower Co., Ltd…………………….………………………………………………………25 LiuShun Automation Equipment Co., Ltd.………………………………………………………………….....27 Dezhou Huizhong Automobile Sales Co. Ltd. ………………………………………………………………..29 Leling Derum Health Food Co., Ltd…………………………………………………………………………........31 Shandong Yichang Lighting Technology Co, Ltd……………………………………………………….......33 Shandong Jitai Welding Materials Co., Ltd……………………………………………………………………35 Shandong Derun New Material Technology Co., Ltd…………………………………….……………….37 Shandong Fuyang Biotechnology Co., Ltd ……………………………………………………………………39 Ji'nan Hua Kaiyuan Co., Ltd………………………………………………………………………………………...41 Shandong HuaQiang New Material Co., Ltd………………………………………………………………….43 China Huayang Economic and Trade Group Co., Ltd. (HuayangGroup)……………………………………………………………………………………………………….45 1 Social
    [Show full text]
  • Efficacy of Small‑Dose Ganciclovir on Cytomegalovirus Infections in Children and Its Effects on Liver Function and Mir‑UL112‑3P Expression
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 22: 912, 2021 Efficacy of small‑dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR‑UL112‑3p expression QINGXIU WANG1*, WENZENG ZHOU2*, BIN WANG3, GUOYUN QIN4, FENG'AI LIU5, DEXIANG LIU6 and TENGTENG HAN2 1Office of Hospital Infection Management, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031; 2Department of Child Rehabilitation, Zaozhuang Maternal and Child Health Hospital of Shandong Province, Zaozhuang, Shandong 277100; 3Department of Child Rehabilitation, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600; 4Department of Pharmacy, Yidu Central Hospital, Weifang, Shandong 262500; 5Department of Paediatrics, Haiyang People's Hospital of Shandong Province, Haiyang, Shandong 265100; 6Department of Pediatrics, Laoling People's Hospital, Laoling, Shandong 253600, P.R. China Received April 3, 2020; Accepted February 1, 2021 DOI: 10.3892/etm.2021.10344 Abstract. The aim of the study was to explore the efficacy treatment, there was also no significant difference between the of small‑dose ganciclovir on cytomegalovirus infections as two groups in miR‑UL112‑3p, TB, ALT, and AST, while after well as its effects on the liver function and miR‑UL112‑3p treatment, both groups showed lower levels of miR‑UL112‑3p, of children. A total of 141 children infected with cyto‑ TB, ALT, and AST, and the Obs group showed significantly megalovirus admitted to the Affiliated Hospital of Weifang lower levels thereof than the Con group (all P<0.05). In addi‑ Medical University from May 2015 to August 2017 were tion, the area under the curve (AUC), specificity, and sensitivity enrolled, of which 74 children were treated with small‑dose of miR‑UL112‑3p in the ROC curve of the Obs group were ganciclovir as an observation group (Obs group), and the rest 0.866, 73.77 and 84.62%, respectively, while the AUC, speci‑ were treated with conventional‑dose ganciclovir as a control ficity, and sensitivity of the ROC of the Con group were 0.837, group (Con group).
    [Show full text]
  • The Lower Precambrian of China
    Revista Brasileira de Geociências 12(1-3): 65-73, Mar.-Set., 1982 - São Paulo THE LOWER PRECAMBRIAN OF CHINA CHENG YUQI*, DAI JlN" and SUN DAZHONG** AB5TRACT IThe Lower Precambrian of China consists of Archean and Lower Proterozoic formations formed probably prior to ca. 1,800-1,900 Ma. They are exposed chiefly in the North China Platform. Archean rocks are composed mainly of gneisses, granulitite and plagloclase-amphibolite of the amphibolite facies, with the lower part containing pyroxene-gneiss and granulite of the granu­ lite fades. The parent rocks were not well differentiated sedimentaries and volcanics, forming two volcano-sedimentary cycles. During the Archean (before 2,500-2,600 Ma), the tectonic en­ vironment over an extensive area .was quite uniform yet fairly active. Towards the end of Archean there prevailed median- to high-grade metamorphism often accompanied by rather intensive mig­ matization. ln the first Early Proterozoíc epoch, a thick sequence of volcano-sedimentaries were accumu­ lated in some marine troughs regarded as eugeosynclinal and developed on the Archean sialic basement, such as the Wutai Group. The protoliths were lhe rather widespread volcanics, the "semipelitic" and pelitic types and turbidites, mainly of greenschisr fades and partly amphibolite facies, occasionally accompanied by migmatization probably not later than 2,300 Ma. After that, a stratigraphic pile accumulated in the miogeosynclinal basins or troughs as rep­ resented by lhe HutuoGroup, and was composed of coarser clastics. pelitics and stromatclite­ -bearing Mg-rich carbonates which show rhythmic deposition. Their greenschist metamorphism probably occurred during ca. I ,800~1 ,900 Ma and this marked the end of the Early Precambrian history.
    [Show full text]
  • Annual Report 2016
    CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA ANNUAL REPORT 2016 ONE HUNDRED FOURTEENTH CONGRESS SECOND SESSION OCTOBER 6, 2016 Printed for the use of the Congressional-Executive Commission on China ( Available via the World Wide Web: http://www.cecc.gov VerDate Mar 15 2010 10:00 Oct 06, 2016 Jkt 000000 PO 00000 Frm 00001 Fmt 6011 Sfmt 5011 U:\DOCS\AR16 NEW\21471.TXT DEIDRE 2016 ANNUAL REPORT VerDate Mar 15 2010 10:00 Oct 06, 2016 Jkt 000000 PO 00000 Frm 00002 Fmt 6019 Sfmt 6019 U:\DOCS\AR16 NEW\21471.TXT DEIDRE CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA ANNUAL REPORT 2016 ONE HUNDRED FOURTEENTH CONGRESS SECOND SESSION OCTOBER 6, 2016 Printed for the use of the Congressional-Executive Commission on China ( Available via the World Wide Web: http://www.cecc.gov U.S. GOVERNMENT PUBLISHING OFFICE 21–471 PDF WASHINGTON : 2016 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Mar 15 2010 10:00 Oct 06, 2016 Jkt 000000 PO 00000 Frm 00003 Fmt 5011 Sfmt 5011 U:\DOCS\AR16 NEW\21471.TXT DEIDRE CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA LEGISLATIVE BRANCH COMMISSIONERS House Senate CHRISTOPHER H. SMITH, New Jersey, MARCO RUBIO, Florida, Cochairman Chairman JAMES LANKFORD, Oklahoma ROBERT PITTENGER, North Carolina TOM COTTON, Arkansas TRENT FRANKS, Arizona STEVE DAINES, Montana RANDY HULTGREN, Illinois BEN SASSE, Nebraska DIANE BLACK, Tennessee DIANNE FEINSTEIN, California TIMOTHY J. WALZ, Minnesota JEFF MERKLEY, Oregon MARCY KAPTUR, Ohio GARY PETERS, Michigan MICHAEL M.
    [Show full text]
  • Factors Affecting Nitrogen Use Efficiency and Grain Yield Of
    sustainability Article Factors Affecting Nitrogen Use Efficiency and Grain Yield of Summer Maize on Smallholder Farms in the North China Plain Guangfeng Chen 1,† ID , Hongzhu Cao 2,†, Jun Liang 3, Wenqi Ma 2, Lufang Guo 1, Shuhua Zhang 1, Rongfeng Jiang 1, Hongyan Zhang 1,* ID , Keith W. T. Goulding 4 ID and Fusuo Zhang 1 1 College of Resources and Environmental Sciences, China Agricultural University, Beijing 100193, China; [email protected] (G.C.); [email protected] (L.G.); [email protected] (S.Z.); [email protected] (R.J.); [email protected] (F.Z.) 2 College of Resources and Environment Science, Hebei Agricultural University, Baoding 071001, Hebei, China; [email protected] (H.C.); [email protected] (W.M.) 3 Agricultural Bureau of Laoling County, Dezhou 253600, Shandong, China; [email protected] 4 Department of Sustainable Agricultural Sciences, Rothamsted Research, Harpenden, Hertfordshire AL5 2JQ, UK; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Received: 10 December 2017; Accepted: 23 January 2018; Published: 31 January 2018 Abstract: The summer maize yields and partial factor productivity of nitrogen (N) fertilizer (PFPN, grain yield per unit N fertilizer) on smallholder farms in China are low, and differ between farms due to complex, sub-optimal management practices. We collected data on management practices and yields from smallholder farms in three major summer maize-producing sites—Laoling, Quzhou and Xushui—in the North China Plain (NCP) for two growing seasons, during 2015–2016. Boundary line analysis and a Proc Mixed Model were used to evaluate the contribution of individual factors and −1 −1 their interactions.
    [Show full text]
  • Federal Register/Vol. 69, No. 59/Friday, March 26, 2004/Notices
    15788 Federal Register / Vol. 69, No. 59 / Friday, March 26, 2004 / Notices DEPARTMENT OF COMMERCE forward the public presentation the Department’s regulations, we are materials to the following address: Ms. initiating those administrative reviews. Bureau of Industry and Security Lee Ann Carpenter, Advisory The Department of Commerce also Committees MS: 1099D, 15th St. & received requests to revoke two Materials Technical Advisory Pennsylvania Ave., NW., U.S. antidumping duty orders in part. Committee; Notice of Open Meeting Department of Commerce, Washington, EFFECTIVE DATE: March 26, 2004. The Materials Technical Advisory DC 20230. FOR FURTHER INFORMATION CONTACT: Committee (MTAC) will meet on April For more information contact Lee Ann Holly A. Kuga, Office of AD/CVD 15, 2004, 10:30 a.m., in the Herbert C. Carpenter on (202) 482–2583. Enforcement, Import Administration, Hoover Building, Room 3884, 14th Dated: March 23, 2004. International Trade Administration, Street between Constitution & Lee Ann Carpenter, U.S. Department of Commerce, 14th Pennsylvania Avenues, NW., Committee Liaison Officer. Street and Constitution Avenue, NW., Washington, DC. The Committee [FR Doc. 04–6795 Filed 3–25–04; 8:45 am] Washington, DC 20230, telephone: (202) advises the Office of the Assistant BILLING CODE 3510–JT–M 482–4737. Secretary for Export Administration with respect to technical questions that SUPPLEMENTARY INFORMATION: affect the level of export controls DEPARTMENT OF COMMERCE Background applicable to advanced materials and related technology. International Trade Administration The Department has received timely requests, in accordance with 19 CFR Agenda Initiation of Antidumping and 351.213(b)(2002), for administrative 1. Opening remarks. Countervailing Duty Administrative reviews of various antidumping and 2.
    [Show full text]
  • Original Article Placental Pathological Manifestations and Expression
    Int J Clin Exp Med 2020;13(5):3355-3362 www.ijcem.com /ISSN:1940-5901/IJCEM0107940 Original Article Placental pathological manifestations and expression levels of apoptosis-related genes and HSP-70 in fetal distress and premature rupture of membranes Yuexia Song1*, Qiaohua Li2*, Zhongting Fan3, Weixia Wang1, Guiping Xu4 1Department of Obstetrics, Laoling People’s Hospital, Laoling, Shandong Province, China; 2Department of Obstet- rics, Linqing Municipal People’s Hospital, Linqing, Shandong Province, China; 3Department of Obstetrics, Weifang Hospital of Maternal and Child Health, Weifang, Shandong Province, China; 4Department of Obstetrics, Zibo City Linzi District People’s Hospital, Zibo, Shandong Province, China. *Equal contributors and co-first authors. Received January 15, 2020; Accepted March 3, 2020; Epub May 15, 2020; Published May 30, 2020 Abstract: Objective: The present study was designed to investigate the pathological manifestations, cell apoptosis and the expression of heat shock protein (HSP)-70 in postpartum placenta of patients with fetal distress or pre- mature rupture of membranes (PROM). Methods: The pathological changes, apoptosis and HSP-70 expression of placenta in 35 cases of fetal distress, 40 cases of premature rupture of membranes and 30 cases of normal de- livery were retrospectively analyzed. Results: Compared with the normal placenta group, the placental pathological manifestations of the fetal distress group and the PROM group showed increased apoptosis of villous trophoblasts and decidual cells (P<0.001). Reverse transcription PCR (RT-PCR) revealed that the mRNA levels of apoptotic genes CDKN1A and BAX were significantly elevated (P<0.001). The expression level of HSP-70 in cells was also found to be markedly increased as measured by Western blot (P<0.01).
    [Show full text]
  • Original Article the Effects of Reduning Injection As an Adjuvant of Azithromycin-Based Therapy for Mycoplasma Pneumoniae and Asthma in Children
    Int J Clin Exp Med 2019;12(12):13643-13650 www.ijcem.com /ISSN:1940-5901/IJCEM0101256 Original Article The effects of reduning injection as an adjuvant of azithromycin-based therapy for mycoplasma pneumoniae and asthma in children Yu Cui1*, Dexiang Liu2*, Zhigang Sun3, Lei Gao1, Hongmin Wang1, Yingjie Hua4, Feng’ai Liu5 Departments of 1Pediatrics, 4Emergency Pediatrics, Zibo City Linzi District People’s Hospital, Zibo, Shandong Province, China; 2Department of Pediatrics, Laoling People’s Hospital, Laoling, Shandong Province, China; 3Department of Pediatrics, The Second People’s Hospital of Liaocheng, Liaocheng, Shandong Province, China; 5Department of Pediatrics, Haiyang People’s Hospital, Haiyang, Shandong Province, China. *Equal contributors and co-first authors. Received August 21, 2019; Accepted October 10, 2019; Epub December 15, 2019; Published December 30, 2019 Abstract: Objective: To explore the efficacy of reduning injection (RDN) combined with azithromycin for the treatment of mycoplasma pneumoniae infection and asthma in children, and its effects on pulmonary function and inflamma- tory cytokine expression. Methods: Eighty-four children with mycoplasma pneumoniae infection and asthma were randomly divided into an observation and a control group, with 42 cases in each group. The patients in the control group were given azithromycin enteric-coated tablets (10 mg PO QD) plus routine treatment, while the patients in the observation group were treated with an adjunctive RDN injection (10 mL of RDN in 100 mL of 5% dextrose in- jection, intravenous infusion) besides azithromycin and routine treatment. The main outcome measures, including the time to defervescence, the time to the disappearance of shortness of breath, cough and lung rales, the length of the hospital stay, the overall response rate, the incidence of adverse events, as well as the eosinophil count (EOS), eosinophil cationic protein (ECP), and interleukin-8 (IL-8) in the peripheral blood were compared.
    [Show full text]
  • The Spatial and Temporal Prognosis of Oilseed Yield in Shandong Province Yujian Yang, Jianhua Zhu, Shubo Wan, Xiaoyan Zhang
    The Spatial and Temporal Prognosis of Oilseed Yield in Shandong Province Yujian Yang, Jianhua Zhu, Shubo Wan, Xiaoyan Zhang To cite this version: Yujian Yang, Jianhua Zhu, Shubo Wan, Xiaoyan Zhang. The Spatial and Temporal Prognosis of Oilseed Yield in Shandong Province. 4th Conference on Computer and Computing Technologies in Agriculture (CCTA), Oct 2010, Nanchang, China. pp.146-157, 10.1007/978-3-642-18354-6_20. hal- 01563404 HAL Id: hal-01563404 https://hal.inria.fr/hal-01563404 Submitted on 17 Jul 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License The spatial and temporal prognosis of oilseed yield in Shandong Province Yujian Yang* 1, Jianhua Zhu 1, Shubo Wan 2, Xiaoyan Zhang 1 (1. S & T Information Engineering Technology Center of Shandong Academy of Agricultural Science, Jinan 250100, P. R. China 2. Shandong Academy of Agricultural Science, Jinan 250100, P. R. China) Abstract. Based on the data about oilseed yield of 87 country units in Shandong province, the paper performed the Moran’s I computerization to analyze the spatial autocorrelation characteristics of the oilseed yield on country level.
    [Show full text]
  • CHINA SHANSHUI CEMENT GROUP LIMITED 中國山水水泥集團有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 691)
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. CHINA SHANSHUI CEMENT GROUP LIMITED 中國山水水泥集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 691) US$500,000,000 7.50% SENIOR NOTES DUE 2020 (Stock Code: 5880) RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016 Operating revenue for the year 2016 amounted to approximately RMB11,284 million (in accordance with International Financial Reporting Standards), representing an increase of 1.1% from that of 2015; Operating profit for the year 2016 amounted to approximately RMB238 million (in accordance with International Financial Reporting Standards); Loss attributable to equity shareholders of the Company for the year 2016 amounted to approximately RMB738 million (in accordance with International Financial Reporting Standards), representing a decrease of 88.4% from that of 2015; Basic loss per share for the year 2016 was RMB0.22 (in accordance with International Financial Reporting Standards), representing a decrease of 88.4% from that of 2015. 1 CONTENTS (I) Definitions 2 (II) Corporate Information 4 (III) Financial and Business Data Summary 8 (IV) Corporate Profile 10 (V) Management Discussion and Analysis 27 (VI) Report of the Directors 45 (VII) Share Capital
    [Show full text]